디프로필사이클로펜틸산탄틴
Dipropylcyclopentylxanthine | |
 | |
| 임상자료 | |
|---|---|
| ATC 코드 |
|
| 법적현황 | |
| 법적현황 |
|
| 식별자 | |
| |
| CAS 번호 | |
| 펍켐 CID | |
| IUPHAR/BPS | |
| 켐스파이더 | |
| 유니 | |
| 체비 | |
| 켐벨 | |
| CompTox 대시보드 (EPA) | |
| ECHA InfoCard | 100.162.425  |
| 화학 및 물리적 데이터 | |
| 공식 | C16H24N4O2 |
| 어금질량 | 304.394 g·190−1 |
| 3D 모델(JSmol) | |
| 녹는점 | 191 ~ 194°C(376 ~ 381°F) |
| |
| |
| (이게 뭐야?) (iii) | |
8-사이클로펜틸-1,3-디프로필산틴(DPCPX,PD-116,948)은 아데노신A1 수용체에 대한 강력한 선택적 대항제 역할을 하는 약물이다.[1][2]다른 아데노신 수용체 서브타입에 비해 A에1 대한 선택성이 높지만, 다른 크산틴 유도체 DPCPX도 인산염 매개체 역할을 하며, PDE4를 억제하는 데 있어서 거의 로립람만큼 위력이 강하다.[3]그것은 아데노신 A수용체의 animals,[4][5]에서 breathing[6]과 활동의 brain,[7][8]의 다양한 지역에서 규제와 DPCPX 같은 몇가지 중요한 기능에 포함되는 것이 밝혀졌다 기능이 공부하는 것 또한은 hallucinogen-appropriate가 r 행동적 효과를 만들어 내는 것으로 나타났다 사용되어 왔다produ esponding5-HT2A 작용제 DOI와 [9]MDMA에 의해 유도된 도파민 방출로 양수되며,[10] 다양한 항경련제 약물과 상호작용한다.[11][12]
참고 항목
참조
- ^ Martinson EA, Johnson RA, Wells JN (March 1987). "Potent adenosine receptor antagonists that are selective for the A1 receptor subtype". Molecular Pharmacology. 31 (3): 247–52. PMID 3561384.
- ^ Lohse MJ, Klotz KN, Lindenborn-Fotinos J, Reddington M, Schwabe U, Olsson RA (August 1987). "8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 336 (2): 204–10. doi:10.1007/BF00165806. PMID 2825043. S2CID 20549217.
- ^ Ukena D, Schudt C, Sybrecht GW (February 1993). "Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes". Biochemical Pharmacology. 45 (4): 847–51. doi:10.1016/0006-2952(93)90168-V. PMID 7680859.
- ^ Coates J, Sheehan MJ, Strong P (May 1994). "1,3-Dipropyl-8-cyclopentyl xanthine (DPCPX): a useful tool for pharmacologists and physiologists?". General Pharmacology. 25 (3): 387–94. doi:10.1016/0306-3623(94)90185-6. PMID 7926579.
- ^ Moro S, Gao ZG, Jacobson KA, Spalluto G (March 2006). "Progress in the pursuit of therapeutic adenosine receptor antagonists". Medicinal Research Reviews. 26 (2): 131–59. doi:10.1002/med.20048. PMID 16380972. S2CID 13758102.
- ^ Vandam RJ, Shields EJ, Kelty JD (2008). "Rhythm generation by the pre-Bötzinger complex in medullary slice and island preparations: effects of adenosine A(1) receptor activation". BMC Neuroscience. 9: 95. doi:10.1186/1471-2202-9-95. PMC 2567986. PMID 18826652.
- ^ Migita H, Kominami K, Higashida M, Maruyama R, Tuchida N, McDonald F, Shimada F, Sakurada K (October 2008). "Activation of adenosine A1 receptor-induced neural stem cell proliferation via MEK/ERK and Akt signaling pathways". Journal of Neuroscience Research. 86 (13): 2820–8. doi:10.1002/jnr.21742. PMID 18618669. S2CID 10240804.
- ^ Wu C, Wong T, Wu X, Sheppy E, Zhang L (February 2009). "Adenosine as an endogenous regulating factor of hippocampal sharp waves". Hippocampus. 19 (2): 205–20. doi:10.1002/hipo.20497. PMID 18785213. S2CID 2124092.
- ^ Marek GJ (March 2009). "Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats". Neuropharmacology. 56 (8): 1082–7. doi:10.1016/j.neuropharm.2009.03.005. PMC 2706691. PMID 19324062.
- ^ Vanattou-Saïfoudine N, Gossen A, Harkin A (January 2011). "A role for adenosine A(1) receptor blockade in the ability of caffeine to promote MDMA "Ecstasy"-induced striatal dopamine release". European Journal of Pharmacology. 650 (1): 220–8. doi:10.1016/j.ejphar.2010.10.012. PMID 20951694.
- ^ De Sarro G, Donato Di Paola E, Falconi U, Ferreri G, De Sarro A (December 1996). "Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene". European Journal of Pharmacology. 317 (2–3): 239–45. doi:10.1016/S0014-2999(96)00746-7. PMID 8997606.
- ^ Chwalczuk K, Rubaj A, Swiader M, Czuczwar SJ (2008). "[Influence of the antagonist of adenosine A1 receptors, 8-cyclopentyl-1 ,3-dipropylxanthine, upon the anticonvulsant activity of antiepileptic drugs in mice]". Przegla̧d Lekarski (in Polish). 65 (11): 759–63. PMID 19205356.
